(Q44743233)

5 December 2017

Impact of vaccinating boys and men against HPV in the United States (English)

1 reference

5 December 2017

Elamin H Elbasha

1

1 reference

PubMed ID

20713101

5 December 2017

Erik J Dasbach

series ordinal

2

1 reference

PubMed ID

20713101

5 December 2017

language of work or name

English

0 references

publication date

14 August 2010

1 reference

5 December 2017

1 reference

5 December 2017

28

1 reference

5 December 2017

42

1 reference

5 December 2017

6858-6867

1 reference

Global cancer statistics, 2002

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Cost-effectiveness of human papillomavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Health and economic implications of HPV vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Age-based programs for vaccination against HPV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Epidemiology of Genital Human Papillomavirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

A multi-type HPV transmission model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

An age-structured model for pertussis transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Modeling for health care and other policy decisions: uses, roles, and validity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

The health and economic burden of genital warts in a set of private health plans in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

The economic burden of noncervical human papillomavirus disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Abnormal outcomes following cervical cancer screening: event duration and health utility loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Quality of life in long-term cervical cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Use of the Pediatric Quality of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Cost-effectiveness of hepatitis B vaccination of prison inmates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.030

10.1016/J.VACCINE.2010.08.030

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference

PubMed ID

20713101